Immuron Limited has appointed LifeSci Capital as its exclusive financial advisor to explore strategic initiatives aimed at maximizing shareholder value. Potential strategies include mergers, acquisitions, licensing, or other transactions, though no specific outcomes are guaranteed. The company will only provide updates if a transaction is approved by its Board or if disclosure is required. Immuron specializes in biopharmaceuticals, particularly orally delivered antibodies for infectious diseases, with products like Travelan® for travelers' diarrhea and developing therapies for Clostridioides difficile infection and IBS.
Immuron's strategic advisory engagement is the subject, with Pluang's health sector data providing context. For readers following health stocks, 70 of 150 US health-sector stocks rose while 65 fell. Notable movers include CGC at USD 0.65 (+4.37%, 79% Sell), HIMS at USD 22.04 (-3.92%, 100% Buy), and ABCL at USD 12.98 (+3.84%, 93% Sell). Data is as of Nov 10, 2026 17:11 WIB.
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
The global paracetamol market is projected to grow from $12.05 billion in 2026 to $15.39 billion by 2032, with a CAGR of 4.12%. Growth is driven by increasing demand for pain and fever management, expanded access to over-the-counter medicines, and in...
ESET Research uncovered a sophisticated cyberespionage tool named Cereal, used by the Russia-aligned Turla group to spy on emails within Microsoft Exchange servers of governmental organizations in Kazakhstan and Romania. The tool stealthily collects ...
Registration is now open for Brand Licensing Expo 2027, scheduled for May 25-27 at Mandalay Bay, Las Vegas. The event, rebranded from Licensing Expo, features over 265 confirmed exhibitors including major brands like Amazon MGM Studios, Coca-Cola, an...
Wix reported Q3 2026 earnings per share of $1.42, surpassing the $1.40 estimate, and revenue of $570.2 million, exceeding the $566.3 million forecast. Bookings grew 11% to $573 million, with revenue up 13%, driven mainly by Base44's strong performanc...
